#biosimilars

[ follow ]
#drug-pricing #q1-2026-earnings #pharmaceuticals #medtech #pipeline-strategy #biologics #fda-regulation #fda
Business
from24/7 Wall St.
4 days ago

Two Paths to Growth: Johnson & Johnson vs AbbVie

Johnson & Johnson and AbbVie beat Q1 2026 revenue expectations and raised full-year guidance using different growth engines despite biosimilar pressures.
US politics
fromwww.aljazeera.com
6 months ago

Why are biologic drugs expensive? Will Trump's plans make them cheaper?

FDA aims to speed biosimilar approvals to increase competition, but experts warn drug prices may not drop quickly.
fromIPWatchdog.com | Patents & Intellectual Property Law
8 months ago

Other Barks & Bites for Friday, September 12: Novartis Loses Challenge to IRA Drug Price Negotiation Program; Lutnick Wants a Share of University IP Licensing; and EUIPO Announces First Copyright Conference

This week in Other Barks & Bites: the European Union Intellectual Property Office announces that it will host its first two-day Copyright Conference in November; the D.C. Circuit finds that Shira Perlmutter showed a likelihood of irreparable harm in granting injunctive relief allowing her to temporarily resume her role as Register of Copyrights; Novartis becomes the latest pharmaceutical company to lose constitutional challenges to the IRA Drug Price Negotiation
Intellectual property law
[ Load more ]